Linked Life Data

7752655

Source:http://linkedlifedata.com/resource/pubmed/id/7752655

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1995-6-22
pubmed:abstractText
We examined the effects of two therapeutic oral (p.o.) doses of cicletanine (50 and 100 mg daily) on renal hemodynamics and segmental tubular handling of sodium. Six normotensive (NT) healthy subjects (group 1) received 50 mg cicletanine, and 12 moderately hypertensive (HT) patients with normal sodium diet and randomly divided into two groups of 6 were treated either with cicletanine 50 mg (group II) or with cicletanine 100 mg (group III). Studies were performed both acutely and after 4 weeks of cicletanine administration. After 28-day treatment, blood pressure (BP) was significantly reduced in HT patients. In NT subjects (group I) and HT patients (groups II and III), acute administration of cicletanine 50 or 100 mg at day 0 did not significantly modify glomerular filtration rate (GFR) or renal blood flow (RBF), but markedly increased fractional excretion of Na (FENa) by 67% in group I and by 62 and 135% in groups II and III, respectively. Fractional distal reabsorption of Na (FDRNa) was significantly reduced in the three groups after cicletanine administration. After 4-weeks treatment, GFR and RBF were not significantly modified. The increase in FeNa and decrease in FDRNa were of the same magnitude as that at day 0. No major changes occurred in hormonal profile [renin, aldosterone, atrial natriuretic factor (ANF)]. Even at low doses, cicletanine has a natriuretic effect in NT and HT subjects. Unchanged fractional reabsorption of lithium and a significant decrease in FDRNa in the three groups suggest that this natriuretic effect occurs at the distal tubule.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0160-2446
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
292-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:7752655-Administration, Oral, pubmed-meshheading:7752655-Adult, pubmed-meshheading:7752655-Aldosterone, pubmed-meshheading:7752655-Analysis of Variance, pubmed-meshheading:7752655-Antihypertensive Agents, pubmed-meshheading:7752655-Atrial Natriuretic Factor, pubmed-meshheading:7752655-Blood Pressure, pubmed-meshheading:7752655-Dose-Response Relationship, Drug, pubmed-meshheading:7752655-Electrolytes, pubmed-meshheading:7752655-Female, pubmed-meshheading:7752655-Glomerular Filtration Rate, pubmed-meshheading:7752655-Humans, pubmed-meshheading:7752655-Hypertension, Renal, pubmed-meshheading:7752655-Kidney Tubules, pubmed-meshheading:7752655-Male, pubmed-meshheading:7752655-Middle Aged, pubmed-meshheading:7752655-Pyridines, pubmed-meshheading:7752655-Renal Circulation, pubmed-meshheading:7752655-Renin, pubmed-meshheading:7752655-Sodium, pubmed-meshheading:7752655-Vascular Resistance
pubmed:year
1995
pubmed:articleTitle
Renal hemodynamics and sodium excretion after acute and chronic administration of cicletanine in normotensive and hypertensive subjects.
pubmed:affiliation
Department of Nephrology, University of Rouen, Paris, France.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial